An anonymous director reports

CLEARMIND MEDICINE RECEIVED APPROVAL FOR A VOLUNTARY DELISTING OF ITS COMMON SHARES FROM THE CANADIAN SECURITIES EXCHANGE

Clearmind Medicine Inc. has applied for and received approval for a voluntary delisting of its common shares from the Canadian Securities Exchange (CSE). The delisting from the CSE will not affect the company's listing on the Nasdaq Capital Market. The common shares will continue to trade on the Nasdaq under the symbol CMND.

The company believes that the trading volume of its shares on the CSE no longer justifies the expenses and administrative efforts required to maintain a dual listing. The company also believes that delisting from the CSE will create a central marketplace for its common shares on the Nasdaq, and ultimately benefit the long-term liquidity and shareholder value of the company.

It is anticipated that, effective as at the close of trading on March 14, 2024, Clearmind's common shares will no longer be listed and posted for trading on the CSE.

Following delisting from the CSE, Clearmind's shareholders can trade their common shares through their brokers on Nasdaq. As most brokers in Canada, including many discount and on-line brokers, have the ability to buy and sell securities listed on Nasdaq, Clearmind's Nasdaq listing will continue to provide shareholders with the same accessibility to trade the company's common shares. Shareholders holding shares in Canadian brokerage accounts should contact their brokers to confirm how to trade Clearmind's shares on the Nasdaq.

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The company's intellectual portfolio currently consists of 15 patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

We seek Safe Harbor.